"In June 2013, Morphosys licensed it's monoclonal antibody MOR202 to Celgene for a $92m upfront payment, $60m milestone payments and double digit royalties. MOR202 is still in Phase 1/2 trials, slightly behind PAB."
Anything can happen here :)
There is absolutely no reason why we can't also get a deal NOW.
IMO
running out of ammo?, page-39
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 40042144 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10681500 | 13 |
View Market Depth
| Last trade - 16.12pm 05/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable